You are here: Industry Insights > Eli Lilly

News List

Lilly’s mirikizumab superior to Cosentyx in phase 3 study for patients with moderate to severe plaque psoriasis pharmaceutical-business-review
July 22, 2020
Eli Lilly and Company announced that mirikizumab, an investigational monoclonal antibody that binds to the p19-subunit of IL23, met the primary and all key secondary endpoints versus placebo at Week 16 (superiority) and ...
Lilly begins world's first study of a potential COVID-19 antibody treatment in humans worldpharmanews
June 29, 2020
Eli Lilly and Company announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19.
Lilly Begins Baricitinib Trial for Hospitalized COVID-19 Patients americanpharmaceuticalreview
June 24, 2020
Eli Lilly and Company announced the first patient has been enrolled in a Phase 3 randomized, double-blind, placebo–controlled study to evaluate the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor licensed from Incyte.
Lilly Begins Study for Second Potential COVID-19 Antibody Treatment americanpharmaceuticalreview
June 17, 2020
Eli Lilly and Company announced its partner Junshi Biosciences has dosed the first healthy volunteer in a study of a potential neutralizing antibody treatment designed to fight COVID-19.
Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients prnewswire
June 16, 2020
Eli Lilly and Company announced that the first patient has been enrolled in a Phase 3 randomized, double-blind, placebo–controlled study to evaluate the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor licensed from Incyte, ...
Second of Lilly’s COVID-19 neutralising antibodies begins Phase I trials europeanpharmaceuticalreview
June 11, 2020
The first patient has been dosed in the Chinese Phase I trial of JS016 in healthy people who do not have a COVID-19 diagnosis.
Lilly and Junshi Biosciences Initiate Phase I COVID-19 Trials contractpharma
June 10, 2020
Studies will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of JS016 in healthy participants who have not been diagnosed with COVID-19.
Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment prnewswire
June 09, 2020
Eli Lilly and Company announced its partner Junshi Biosciences has dosed the first healthy volunteer in a study of a potential neutralizing antibody treatment designed to fight COVID-19.
Lilly bags expanded EU approval for Taltz pharmatimes
June 08, 2020
The European Medicines Agency has expanded the reach of Lilly's Taltz (ixekizumab) to include the treatment of adults with active ankylosing spondylitis and active non-radiographic axial spondyloarthritis (nr-axSpA).
Shanghai Junshi Biosciences starts human tests for coronavirus antibody drug expresspharma
June 08, 2020
The experimental drug, JS016, is also expected to begin human study in the US in the second quarter of this year, through collaboration with Eli Lilly and Co.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page